ClinicalTrials.gg

Program

nemtabrutinib

In Merck's pipeline, Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of onc. Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Hematologic Neoplasms · Renal Insufficiency · Lymphoma, Large B-Cell, Diffuse, led by Merck.

Furthest: phase 3, since Nov 14, 202216 company-led studies, 7 open or runningNext primary completion: Feb 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck167 open or runningphase 3since Nov 14, 2022May 15, 2017Feb 1, 2027phase 1 · NCT07734610
  • Named in Merck’s own pipeline as nemtabrutinib (MK-1026), phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2017First study: phase 2 study in Lymphoma, B-CellFirst studyNCT03162536 · 190 enrolled · United States
  2. Jan 25, 2021Phase 2 study in Hematologic NeoplasmsNCT04728893 · 490 planned · United States, Argentina, Australia and more
  3. Apr 20, 2022Phase 1 study in Hematologic NeoplasmsNCT05347225 · 12 enrolled · China
  4. Nov 14, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05624554 · 300 enrolled · United States, Australia, Brazil and more
  5. Jan 4, 2023Phase 1 study in Mature B-cell NeoplasmsNCT05673460 · 7 enrolled · Japan
  6. Jul 7, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05947851 · 735 planned · United States, Argentina, Australia and more
  7. Nov 13, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06136559 · 1,200 planned · United States, Australia, Belgium and more
  8. May 29, 2024Phase 1 study in Hepatic Impairment (HI)NCT06442436 · 24 enrolled · United States
  9. Sep 4, 2024Phase 1 study in Hematologic NeoplasmsNCT06586671 · 40 enrolled · United States
  10. Oct 1, 2024Phase 1 study in HealthyNCT06625827 · 24 enrolled · United States
  11. Nov 12, 20242 phase 1 studies in HealthyNCT06688045, NCT06698016
  12. Jan 9, 20252 phase 1 studies in HealthyNCT06772818, NCT06772805
  13. Nov 14, 2025Phase 1 study in HealthyNCT07232589 · 26 enrolled · United States
  14. Jul 20, 2026Phase 1 study in Renal InsufficiencyNCT07734610 · 20 planned · United States

Ahead

  1. Feb 1, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07734610
  2. Apr 30, 2027Primary completion: phase 1 study in Hematologic NeoplasmsNCT05347225
  3. May 19, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05624554
  4. Sep 17, 2027Primary completion: phase 2 study in Lymphoma, B-CellNCT03162536

TargetBeta

“Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of onc”the company's pipeline, read by Claude · source
“An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07734610Renal Insufficiency · United States1RecruitingFeb 1, 202720
NCT07232589Healthy · United States1CompletedMay 4, 202626
NCT06772818Healthy · United States1CompletedDec 20, 202320
NCT06772805Healthy · United States1CompletedDec 12, 202318
NCT06698016Healthy · United States1CompletedOct 30, 202316
NCT06688045Healthy · United States1CompletedJan 6, 202415
NCT06625827Healthy · United States1CompletedJan 22, 202424
NCT06586671Hematologic Neoplasms · United States1CompletedNov 13, 202340
NCT06442436Hepatic Impairment (HI) · United States1CompletedAug 13, 202624
NCT06136559Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3RecruitingSep 7, 20321,200
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingJun 1, 2032735
NCT05673460Mature B-cell Neoplasms · Japan1CompletedApr 28, 20257
NCT05624554Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more3Active, not recruitingMay 19, 2027300
NCT05347225Hematologic Neoplasms · China1Active, not recruitingApr 30, 202712
NCT04728893Hematologic Neoplasms · United States, Argentina, Australia and more2RecruitingJan 4, 2029490
NCT03162536Lymphoma, B-Cell · United States2Active, not recruitingSep 17, 2027190

How it is read

Names in the registry

  • “Nemtabrutinib”, 16 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.